分子水平生药研究的国内文献计量分析  

Development of molecular pharmacognosy in China based on bibliometric analysis

作　　者：刘扬[1] 王俊文[1] 童元元[1] 杨策[1] 黄满婷 雷蕾[1] 李海燕[1] 

机构地区：[1]中国中医科学院中医药信息研究所,北京100700

出　　处：《中国中药杂志》2016年第6期1161-1164,共4页China Journal of Chinese Materia Medica

基　　金：中国中医科学院科技创新团队项目(PY1306);中国中医科学院客座研究员联合创新研究项目(ZZ070822)

摘　　要：该文利用文献计量学的方法,对1995—2015年CNKI中国学术期刊网络出版总库中发表的有关分子水平生药研究的论文以及上海知识产权(专利)公共服务平台的相关授权专利进行检索和分析,发现经历了20年的发展,该领域论文总量达22 462篇,论文基金资助率达63%;涉及50家核心研究机构、888位核心作者、18种核心期刊;授权专利有496项,涉及中药材90种。从论文和专利的数量,期刊、机构和作者群的规模以及领域分类的广泛程度上,都说明分子生物技术与生药学的关系越来越密切,已形成一个发展迅速、富有前景的交叉研究领域。The method of bibliometrics was used to analyze the literature about the application of molecular biotechnique to pharmacognosy which were searched and obtained from the CNKI database and Shanghai intellectual property information platform from the year1995 to 2015. It was found that 22 462 articles were published and the 63% were funded,50 core institutions and 888 authors,18 core journals were engaged in this subject. 496 items of patents were authorized and 90 kinds of Chinese Materia Medica were involved. In the view of the quantity and quality of published literature,the scale and influence of journals,institutions,and the extent of subject categories have made remarkable achievement. Molecular pharmacognosy has completed the germination stage of a new subject,and has been in a relatively mature and stable development status.

关 键 词：分子生药学 文献计量分析 科技评价 

分 类 号：G353.1[文化科学—情报学] R284[医药卫生—中药学]